Patent ID: 8092828

Claim:
A method to treat a leukemia in a human patient, said method comprising administering intravenously to said patient a pharmaceutical composition comprising cytarabine and daunorubicin at a fixed, molar ratio of cytarabine to daunorubicin of about 5:1 in an administration step of 8 hours or less, wherein said fixed ratio is maintained in the plasma for at least 4 hours, and wherein said fixed, molar ratio of cytarabine and daunorubicin is encapsulated in liposomes; wherein the composition is administered to provide cytarabine in an amount of 32-134 mg/m 2 and a total amount of 96-402 mg/m 2 in a cycle of administration consisting of a first administration step on day 1, a second administration step on day 3, and a third administration step on day 5; and wherein the liposomes comprise DSPC:DSPG:cholesterol at 7:2:1 molar ratio.